Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Hasan Rizvi et al.|The Lancet|2021Cited by 315
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound AssessmentChristopher Holroyd, Christopher J Edwards, Brittany I Davidson et al.|Oxford University Research Archive (ORA) (University of Oxford)|2013Cited by 2